For following the competition: what moved in each program, several studies read as one move.
- vilobelimab
- NI-0101
- Bevacizumab
- + 2 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Acute Lung Injury to watchlistEvery Monday by email · turn it off any timePro · free during the beta